Sandoz launches AirFluSal® Forspiro® in Norway

Holzkirchen, April 2, 2014 – Sandoz announces today that it is launching in Norway AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

​The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Hungary, Romania and Bulgaria. In February, Sandoz received its first marketing approval in Asia, with marketing authorization in South Korea.

In Norway, Sandoz is launching the 50/250µg and 50/500µg dosage forms for the continuous …

/by

Sandoz launches first generic version of Taclonex® Ointment

Princeton, New Jersey, April 1, 2014 – Sandoz today announced the US market introduction of its calcipotriene and betamethasone dipropionate ointment, the first generic version of Leo Pharma’s Taclonex® Ointment.

​Calcipotriene and betamethasone dipropionate ointment is a vitamin D analogue and corticosteroid combination product indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and older.

Psoriasis affects approximately 2% of the US population. Plaque psoriasis is the most common form of the condition. [1]

“Sandoz is …

/by

Vas Narasimhan to lead Sandoz’biosimilars business

Munich, Germany, March 27, 2014 – Sandoz announced today that Vasant (Vas) Narasimhan, MD, MPP, has been appointed Head of Sandoz Biopharmaceuticals & Oncology Injectables effective April 1, 2014. Vas, currently Global Head of Development at Novartis Vaccines, succeeds Ameet Mallik who will take on a new leadership role at Novartis Oncology. Vas will be responsible for biosimilars, oncology injectables, the biotechnology contract manufacturing business, as well as Sandoz’ industry-leading biosimilars pipeline.

“I am deeply grateful for Ameet’s outstanding …

/by

Sandoz receives approval for biosimilar filgrastim in Japan

  • Sandoz Filgrastim approved in all indications as the reference product
  • Sandoz becomes first company to secure approval for two biosimilars in Japan
  • Approval marks continued expansion of Sandoz’ biosimilar business
…
/by

Tuberculosis remains a global health challenge; Sandoz continues commitment to fighting the disease

March 21, 2014 – Despite great progress made in the fight to eradicate Tuberculosis (TB), the disease remains a global killer and disproportionately affects the world’s poor. Sandoz, a leading provider of high-quality, affordable generic medicines, has the opportunity to significantly contribute to the fight against TB.

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent, according to the World Health Organization. In 2012, 8.6 million people fell ill with TB and 1.3 million died from TB.

…

/by

Sandoz expands Tuberculosis activities in Africa

March 19, 2014 – The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.

Sandoz contributes to fighting Tuberculosis in Egypt

In Egypt, TB constitutes the second most important public health problem, after schistosomiasis. Although Egypt has relatively low levels of TB according to data from the World Health …

/by

Sandoz expands Tuberculosis activities in Africa

March 19, 2014 – The Sandoz Tuberculosis (TB) program is increasing its reach in Africa. Sandoz is expanding its Tuberculosis portfolio as well as its Corporate Responsibility initiatives to support positive health outcomes for more patients and ultimately, contribute towards the eradication of the disease.

Sandoz contributes to fighting Tuberculosis in Egypt

In Egypt, TB constitutes the second most important public health problem, after schistosomiasis. Although Egypt has relatively low levels of TB according to data from the World Health …

/by

South Korea approves AirFluSal® Forspiro®

Munich, Germany, February 28, 2014 – Sandoz announced today it has received South Korean marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.

The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria.

“We are pleased to receive the marketing authorization in South Korea for AirFluSal® Forspiro®. This is our first approval in Asia and outside Europe and a milestone in …

/by

South Korea approves AirFluSal® Forspiro®

Munich, Germany, February 28, 2014 – Sandoz announced today it has received South Korean marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD, marking its first approval in Asia.

The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria.

“We are pleased to receive the marketing authorization in South Korea for AirFluSal® Forspiro®. This is our first approval in Asia and outside Europe and a milestone in …

/by

Sandoz recognizes International Women’s Day, highlighting importance of healthcare access for women globally

March 7, 2014

Today Sandoz recognizes International Women’s Day (IWD), a globally-recognized day which celebrates the economic, social and cultural contributions made by women.

It is observed each year on March 8th. The United Nations theme for IWD this year is “Equality for Women is Progress for All.”

…

/by